

23rd February 2018

Important information for healthcare professionals

Re: Supply of ERWINASE® (Crisantaspase) 10,000 Units/vial, powder for solution for injection, PA 1020/002/001.

UK Batch number: 186G*, expiry date: 10/2020

Dear Pharmacist,

I am writing to you in connection with supply of the above referenced product, ERWINASE® (Crisantaspase) 10,000 Units/vial, powder for solution for injection. We are unable to supply Irish licensed packs at the moment, and have obtained approval from the HPRA to supply UK packs for a limited period.

These UK packs are labelled with batch No. 186G*, with an expiry date of 10/2020.

The pharmaceutical composition of the product is the same, and the name of the product is the same - Erwinase.

Please note that it is important to read the currently approved Irish product information that is attached to those packs.

Some patients, nurses and doctors may note the above differences, and may bring these to your attention. If this occurs, please explain to those patients that the packs they have received from Batch 186G* are compliant and approved for use in Ireland.

Please ensure all relevant staff are made aware of the content of this letter and that the information including potential risks are communicated to the patients. Please ensure that patients receive a copy of the Irish package leaflet.

It is important to read the notice of special handling instructions prior to administering batch 186G* as it details the additional precaution of using a standard 5-micron filter to withdraw the reconstituted product from the vial prior to administration.

If you have any questions, please contact:

Tel: +44 (0) 7500 115092 or +44 (0) 1865 405065

Email: Chris.pitts@jazzpharma.com

Yours sincerely,



Dr. Chris Pitts
Medical Director (UK and Ireland)
Jazz Pharmaceuticals

*BATCH 186G may consist of packaged sub-lots: 186G118, 186G218, 186G318, 186G418 or 186G518